Bococizumab is a novel anti-PCSK9 antibody efficiently developed to address hypercholesterolemia. This therapeutic agent interacts with the PCSK9 protein, a key regulator of cholesterol levels. By neutralizing the https://www.targetmol.com/compound/bococizumab